Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
16729-0426-05 16729-0426 GEMCITABINE GEMCITABINE 100.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Aug. 6, 2018 In Use
16729-0436-30 16729-0436 Fulvestrant FULVESTRANT 250.0 mg/5mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Jan. 21, 2021 In Use
16729-0486-01 16729-0486 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Aug. 24, 2020 In Use
16729-0522-05 16729-0522 Pemetrexed disodium Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 8, 2022 In Use
16729-0522-28 16729-0522 Pemetrexed disodium Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 8, 2022 In Use
16729-0522-35 16729-0522 Pemetrexed disodium Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 8, 2022 In Use
16729-0522-64 16729-0522 Pemetrexed disodium Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 8, 2022 In Use
16729-0542-35 16729-0542 Fluorouracil Fluorouracil 50.0 mg/g Chemotherapy Antimetabolite Pyrimidine Analog Topical Nov. 11, 2021 In Use
16729-0545-63 16729-0545 CARMUSTINE CARMUSTINE Chemotherapy Alkylating Agent Nitrosourea Aug. 18, 2022 In Use
16729-0548-63 16729-0548 CARMUSTINE CARMUSTINE Chemotherapy Alkylating Agent Nitrosourea Aug. 18, 2022 In Use
17156-0524-01 17156-0524 Strontium Chloride Sr-89 Metastron 1.0 mCi/mL Ancillary Therapy Radiopharmaceutical Strontium Sr 89 Intravenous June 18, 1993 Jan. 10, 2019 In Use
17478-0327-05 17478-0327 Zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous May 22, 2014 In Use
17478-0327-45 17478-0327 Zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous May 22, 2014 In Use
17478-0546-01 17478-0546 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Oct. 1, 2009 June 1, 2011 In Use
17478-0546-02 17478-0546 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Oct. 1, 2009 In Use
17478-0546-04 17478-0546 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Oct. 1, 2009 June 1, 2011 In Use
17478-0546-05 17478-0546 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Oct. 1, 2009 In Use
17478-0547-01 17478-0547 Granisetron Hydrochloride Granisetron Hydrochloride 0.1 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Oct. 1, 2009 In Use
17478-0761-06 17478-0761 Dronabinol Dronabinol 2.5 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 20, 2014 In Use
17478-0762-06 17478-0762 Dronabinol Dronabinol 5.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 20, 2014 In Use
17478-0763-06 17478-0763 Dronabinol Dronabinol 10.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 20, 2014 In Use
17856-0032-01 17856-0032 Letrozole Letrozole 2.5 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Jan. 13, 2020 In Use
17856-0090-01 17856-0090 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Jan. 11, 2021 In Use
17856-0691-01 17856-0691 Ondansetron Ondansetron 4.0 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 17, 2024 In Use
17856-0691-02 17856-0691 Ondansetron Ondansetron 4.0 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 17, 2024 In Use

Found 10,000 results in 8 milliseconds — Export these results